Comparison of the Effectiveness Metformin for Deceasing Proliferative Marker in Endometrial Cancer Cells

• Status: Completed
• Trial end date: 2020-01-07
• Target enrollment: 0
• Participant gender: Female

Summary

Comparison of the effectiveness metformin versus placebo for deceasing proliferative marker Ki-67 expression in endometrial tumours when given for 4 weeks before hysterectomy in endometrial cancer cells.

• Phase: N/A
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Rajavithi Hospital
• Treatments: Metformin

Criteria

Inclusion Criteria:

• Women with endometrial cancer who undergoing complete surgical staging and agrees to participate in this study

Exclusion Criteria:

• Women without diabetes type 1 and 2

• Women who have allergy Biguanide

• Women who have hypoglycemic medication

• Women who have GFR <45 ml/min/1.73 m2

• Women who have evidence of stage 3 or 4 of endometrial cancer